Long-term first-in-man Phase I/II study of an adjuvant dendritic cell vaccine in patients with high-risk prostate cancer after radical prostatectomy
/in Dendritic Cells, International Publications, Prostate CancerCancer Vaccines for Genitourinary Tumors: Recent Progresses and Future Possibilities
/in Dendritic Cells, International Publications, Prostate Cancer, Urothelial CarcinomaMoving on From Sipuleucel-T: New Dendritic Cell Vaccine Strategies for Prostate Cancer
/in Dendritic Cells, International Publications, Prostate CancerHigh Health-Related Quality of Life During Dendritic Cell Vaccination Therapy in Patients With Castration-Resistant Prostate Cancer
/in Dendritic Cells, International Publications, Prostate CancerConsensus guidelines for the definition, detection and interpretation of immunogenic cell death
/in Dendritic Cells, Immunogenic Cell Death, International Publications, Newcastle Disease Virus, Prostate CancerTargeting STAT3 enhances NDV-induced immunogenic cell death in prostate cancer cells
/in Immunogenic Cell Death, International Publications, Newcastle Disease Virus, Prostate CancerSubstantial tumor regression in prostate cancer patient with extensive skeletal metastases upon Immunotherapy (APCEDEN): A case report
/in Dendritic Cells, International Publications, Prostate CancerBlood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer
/in Dendritic Cells, International Publications, Prostate CancerSubstantial remission of prostate adenocarcinoma with dendritic cell therapy APCEDEN in combination with chemotherapy
/in Dendritic Cells, International Publications, Prostate Cancer
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de